ACP3 and metastatic prostate carcinoma: First, treatment of metastatic prostate cancer with sipuleucel-T (also known as APC 8015), a cell product based on enriched blood APCs that are briefly cultured with a fusion protein of prostatic acid phosphatase (PAP) and GM-CSF with the result of an approximately a four month longer median survival in Phase III trials [47,48].